Lv1
50 积分 2025-09-20 加入
Erdafitinib for locally advanced or metastatic urothelial carcinoma
5个月前
已完结
SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations
5个月前
已完结
皖公网安备34019202002308
